Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

BJUI Compass ◽

10.1002/bco2.116 ◽

2021 ◽

Author(s):

Yashar Khoshkar ◽

Marcus Westerberg ◽

Jan Adolfsson ◽

Anna Bill‐Axelson ◽

Henrik Olsson ◽

...

Keyword(s):

Prostate Cancer ◽

Real World ◽

Population Based ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Long Term Follow Up

Download Full-text

Long-Term Androgen Ablation and Docetaxel Up-Regulate Phosphorylated Akt in Castration Resistant Prostate Cancer

The Journal of Urology ◽

10.1016/j.juro.2011.02.016 ◽

2011 ◽

Vol 185 (6) ◽

pp. 2376-2381 ◽

Cited By ~ 26

Author(s):

Takeo Kosaka ◽

Akira Miyajima ◽

Suguru Shirotake ◽

Eriko Suzuki ◽

Eiji Kikuchi ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Androgen Ablation ◽

Castration Resistant ◽

Phosphorylated Akt

Download Full-text

Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes

International Journal of Urology ◽

10.1111/iju.14009 ◽

2019 ◽

Vol 26 (8) ◽

pp. 797-803 ◽

Cited By ~ 4

Author(s):

Nobumichi Tanaka ◽

Kazuo Nishimura ◽

Eijiro Okajima ◽

Kenji Ina ◽

Osamu Ogawa ◽

...

Keyword(s):

Prostate Cancer ◽

Oral Administration ◽

Castration Resistant Prostate Cancer ◽

Long Term Outcomes ◽

Castration Resistant ◽

Daily Oral Administration

Download Full-text

Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032

European Urology ◽

10.1016/j.eururo.2020.09.049 ◽

2021 ◽

Vol 79 (1) ◽

pp. e10-e11

Author(s):

Ethan B. Ludmir ◽

Zachary R. McCaw ◽

Lee-Jen Wei

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Phase Iii ◽

Castration Resistant Prostate Cancer ◽

Phase Iii Trial ◽

Castration Resistant ◽

Long Term Survivors

Download Full-text

Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2016.02.035 ◽

2016 ◽

Vol 70 (3) ◽

pp. 438-444 ◽

Cited By ~ 24

Author(s):

Karim Fizazi ◽

Kim N. Chi ◽

Johann S. de Bono ◽

Leonard G. Gomella ◽

Kurt Miller ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Low Incidence ◽

Dose Prednisone

Download Full-text

Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-018-1265-8 ◽

2018 ◽

Vol 23 (4) ◽

pp. 749-756 ◽

Cited By ~ 2

Author(s):

Rihito Aizawa ◽

Kenji Takayama ◽

Kiyonao Nakamura ◽

Takahiro Inoue ◽

Takashi Kobayashi ◽

...

Keyword(s):

Prostate Cancer ◽

External Beam Radiotherapy ◽

External Beam ◽

Castration Resistant Prostate Cancer ◽

Long Term Outcomes ◽

Castration Resistant

Download Full-text

P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study

European Urology Supplements ◽

10.1016/s1569-9056(13)62445-8 ◽

2013 ◽

Vol 12 (6) ◽

pp. 178

Author(s):

S Nilsson ◽

A.J. Schrader ◽

J. Kliment ◽

A. Solberg ◽

L. Franzén ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Castration Resistant ◽

Radium 223

Download Full-text

PD32-12 LONG-TERM FOLLOW-UP OF CIRCULATING TUMOR CELLS AS PREDICTORS FOR SURVIVAL IN MEN TREATED WITH ABIRATERONE ACETATE FOR CASTRATION RESISTANT PROSTATE CANCER FOLLOWING CHEMOTHERAPY

The Journal of Urology ◽

10.1016/j.juro.2016.02.688 ◽

2016 ◽

Vol 195 (4S) ◽

Author(s):

Christian Meyer ◽

Petra Strölin ◽

Hans Heinzer ◽

Klaus Pantel ◽

Sabine Riethdorf ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Long Term Follow Up

Download Full-text

564 Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

European Urology Supplements ◽

10.1016/s1569-9056(15)60557-7 ◽

2015 ◽

Vol 14 (2) ◽

pp. e564 ◽

Cited By ~ 1

Author(s):

K. Miller ◽

K. Chi ◽

J.S. De Bono ◽

K. Fizazi ◽

L.G. Gomella ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Dose Prednisone

Download Full-text

Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report

American Journal of Case Reports ◽

10.12659/ajcr.930989 ◽

2021 ◽

Vol 22 ◽

Author(s):

Shigehisa Kubota ◽

Susumu Kageyama ◽

Masayuki Nagasawa ◽

Akinori Wada ◽

Ryo Ikari ◽

...

Keyword(s):

Prostate Cancer ◽

Case Report ◽

Prostate Specific Antigen ◽

Low Dose ◽

Specific Antigen ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text